

Inebilizumab for treating immunoglobulin G4-related disease (terminated appraisal)

Technology appraisal guidance
Published: 6 May 2026

www.nice.org.uk/guidance/ta1151

Contents

Advice.....	3
What this means in practice.....	3

Advice

NICE is unable to make a recommendation about the use in the NHS of inebilizumab for treating immunoglobulin G4-related disease. This is because Amgen Ltd has confirmed that it does not intend to make an evidence submission for the evaluation. Amgen Ltd considers that the technology is unlikely to be a cost-effective use of NHS resources.

NICE will review the position if the company decides that it wants to make an evidence submission.

What this means in practice

Inebilizumab should not be routinely commissioned in the NHS in England for the condition and population stated in this terminated evaluation.

This is because an evidence submission was not provided, so NICE is unable to evaluate whether inebilizumab offers benefit and is value for money in this population.

If NHS organisations wish to consider inebilizumab for this indication, they should follow the advice on local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). These outline the approach that should be taken when there is no NICE guidance.

ISBN: 978-1-4731-9453-3